Podcast Skinfluenced - The Skin Podcast by Skinfluenced - The Skin Podcast Links

Analyze shared links from Skinfluenced - The Skin Podcast

Understand the reach and influence of Skinfluenced - The Skin Podcast by exploring the links shared by the creators. Sorted by platform, these links offer a unique perspective into the podcast's content strategy and audience engagement. Discover more about the show's presence across Instagram, YouTube, Apple Podcasts, Spotify, and other platforms.

Links used by the creators in the description of the show or episodes.

Service

Link	Count	Other Shows
https://www.jaad.org/article/S0190-9622	2	+19
https://epicutis.com/products/lipid-serum	2
https://investors.arcutis.com/news-releases/news-release-details/fda-approves-arcutis-zoryver-roflumilast-cream-005-treatment	2
https://www.hcplive.com/view/significance-roflumilast-approval-atopic-dermatitis-children-lawrence-eichenfield-md	2
https://www.hmpgloballearningnetwork.com/site/thederm/fda-alerts/fda-approves-roflumilast-cream-005-treatment-atopic-dermatitis-children	2
https://thedermdigest.com/u-s-fda-approves-roflumilast-cream-0-05-for-ad-in-kids-aged-2-to-5	2
https://www.zoryvehcp.com/	2
https://rdcu.be/ey3d5	2
https://s203.q4cdn.com/636242992/files/doc_news/Johnson--Johnson-seeks-first-icotrokinra-U-S--FDA-approval-aiming-to-revolutionize-treatment-paradigm-for-adults-and-adolescents-with-ABQBI.pdf	2
https://www.researchgate.net/publication/388790490_Pilot_Study_Demonstrates_Tetramethylhexadecenyl_Succinoyl_Cysteine_TSC_Reduces_Tretinoin-Induced_Erythema_and_Dryness_in_Human_Subjects	2
https://www.ajmc.com/view/fda-approves-remibrutinib-for-chronic-spontaneous-urticaria	2
https://www.biospace.com/fda/novartis-secures-first-fda-approval-of-oral-btk-inhibitor-for-chronic-hives	2
https://clinicaltrials.gov/study/NCT05030311	2
https://clinicaltrials.gov/study/NCT05032157	2
https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treatment-chronic-spontaneous-urticaria-csu	2
https://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/	2
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-novartis-drug-skin-disease-2025-09-30/	2
https://www.sciencedirect.com/science/article/pii/S0091674922011812	2
https://www.tandfonline.com/doi/abs/10.1080/1750743X.2025.2510892	2
https://www.businesswire.com/news/home/20210921006072/en/Incyte-Announces-U.S.-FDA-Approval-of-Opzelura-ruxolitinib-Cream-a-Topical-JAK-Inhibitor-for-the-Treatment-of-Atopic-Dermatitis-AD	2
https://www.contemporarypediatrics.com/view/fda-approves-ruxolitinib-for-pediatric-atopic-dermatitis	2
https://investor.incyte.com/node/23156/pdf	2
https://investor.incyte.com/node/23376/pdf	2
https://investor.incyte.com/node/25636/pdf	2
https://investor.incyte.com/node/25226/pdf	2
https://www.pharmacytimes.com/view/fda-approves-1-5-ruxolitinib-cream-for-pediatric-atopic-dermatitis	2
https://www.ajmc.com/view/fda-approves-ruxolitinib-cream-for-patients-as-young-as-2-years-with-atopic-dermatitis	2
https://www.lynchregen.com/wp-content/uploads/2025/09/RPT-001v1.0-A-Review-of-the-Safety-of-Exogenously-Applied-rhPDGF-vFinal.pdf	2
https://academic.oup.com/aje/article/190/9/1814/6175319#354359554	2
https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1427770/full	2
https://pubmed.ncbi.nlm.nih.gov/12558343/	2
https://pubmed.ncbi.nlm.nih.gov/26963841/	2
https://pubmed.ncbi.nlm.nih.gov/27559331/	2
https://pubmed.ncbi.nlm.nih.gov/29900173/	2
https://pubmed.ncbi.nlm.nih.gov/30506967/	2
https://pubmed.ncbi.nlm.nih.gov/31883695/	2
https://pubmed.ncbi.nlm.nih.gov/33237617/	2
https://pubmed.ncbi.nlm.nih.gov/33733653/	2
https://pubmed.ncbi.nlm.nih.gov/40238652/	2
https://www.businesswire.com/news/home/20250723115252/en	2
https://www.leo-pharma.com/media-center/news/2025-fda-approval	2
https://doi.org/10.1007/s13555-025-01384-4	2
https://research.rug.nl/en/publications/efficacy-and-safety-of-delgocitinib-cream-in-adults-with-moderate	2
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563	1	+9
https://www.aacr.org/patients-caregivers/progress-against-cancer/immunotherapy-approved-for-preventing-recurrence-of-certain-skin-cancers/	1
https://www.ajmc.com/view/fda-approves-cemiplimab-as-first-only-adjuvant-immunotherapy-for-high-risk-cscc	1
https://www.dermatologyadvisor.com/news/fda-approves-libtayo-for-adjuvant-treatment-of-high-risk-cscc/	1
https://thedermdigest.com/fda-approves-cemiplimab-to-treat-cscc-with-high-risk-of-recurrence-after-surgery-and-radiation/?utm_source=Klaviyo&utm_medium=campaign&_kx=LStbfMDiK_dFORiyt1p_kkItQ6IXDv9wQWWp60o95yV8qS2-9Wbebg-OUZpTxSvC.TYhhHR	1
https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.6000	1
https://www.onclive.com/view/dr-patel-on-the-fda-approval-of-adjuvant-cemiplimab-for-high-rish-cutaneous-squamous-cell-carcinoma	1
https://www.ons.org/publications-research/voice/news-views/10-2025/fda-approves-cemiplimab-rwlc-adjuvant-treatment	1
https://investor.regeneron.com/news-releases/news-release-details/adjuvant-libtayor-cemiplimab-significantly-improves-disease-free	1
https://newsroom.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-rwlc-approved-us-first-and-only	1
https://newsroom.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-phase-3-data-adjuvant-treatment-post	1
https://www.regeneron.com/downloads/libtayo_fpi.pdf	1
https://www.regeneron.com/downloads/libtayo-medication-guide.pdf	1
https://www.sciencedirect.com/science/article/abs/pii/0168952585900897	1
https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-atopic-dermatitis-in-children-ages-2-to-5/?utm_source=chatgpt.com	1
https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-atopic-dermatitis-in-children-ages-2-to-5/	1
https://www.hcplive.com/view/fda-approves-roflumilast-zoryve-cream-0-05-for-atopic-dermatitis-in-children-aged-2-5-years?utm_source=chatgpt.com	1
https://www.hcplive.com/view/fda-approves-roflumilast-zoryve-cream-0-05-for-atopic-dermatitis-in-children-aged-2-5-years	1
https://www.hcplive.com/view/roflumilast-cream-0-05-effective-atopic-dermatitis-patients-aged-2-5-years?utm_source=chatgpt.com	1
https://www.hcplive.com/view/roflumilast-cream-0-05-effective-atopic-dermatitis-patients-aged-2-5-years	1
https://thedermdigest.com/breaking-news-the-u-s-fda-approves-remibrutinib-rhapsido-novartis-for-csu/?utm_source=Klaviyo&utm_medium=campaign&_kx=LStbfMDiK_dFORiyt1p_kkItQ6IXDv9wQWWp60o95yV8qS2-9Wbebg-OUZpTxSvC.TYhhHR	1
https://thedermdigest.com/breaking-news-the-u-s-fda-approves-remibrutinib-rhapsido-novartis-for-csu/?utm_source=Klaviyo&amp	1
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash?utm_source=chatgpt.com	1
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash	1
https://www.sciencedirect.com/science/article/abs/pii/S0168827820302014?utm_source=chatgpt.com	1
https://www.sciencedirect.com/science/article/abs/pii/S0168827820302014	1
https://pubmed.ncbi.nlm.nih.gov/35650449/?utm_source=chatgpt.com	1
https://pubmed.ncbi.nlm.nih.gov/35650449/	1
https://pubmed.ncbi.nlm.nih.gov/37899788/?utm_source=chatgpt.com	1
https://pubmed.ncbi.nlm.nih.gov/37899788/	1
https://pubmed.ncbi.nlm.nih.gov/39222642/?utm_source=chatgpt.com	1
https://pubmed.ncbi.nlm.nih.gov/39222642/	1
https://pubmed.ncbi.nlm.nih.gov/40004240/?utm_source=chatgpt.com	1
https://pubmed.ncbi.nlm.nih.gov/40004240/	1
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?utm_source=chatgpt.com	1
https://scholarindexing.com/uploads/files/8pu3_1ome6lcxkb.pdf?utm_source=chatgpt.com	1
https://scholarindexing.com/uploads/files/8pu3_1ome6lcxkb.pdf	1
https://lrmaesthetics.com/	1
https://www.dermatologytimes.com/view/fda-approves-delgocitinib-for-chronic-hand-eczemahttps://www.dermatologytimes.com/view/fda-approves-delgocitinib-for-chronic-hand-eczema	1
https://www.dermatologytimes.com/view/fda-approves-delgocitinib-for-chronic-hand-eczema	1

About us Privacy Policy